Pornchai O-Charoenrat
Overview
Explore the profile of Pornchai O-Charoenrat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
896
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thongchot S, Aksonnam K, Prasopsiri J, Warnnissorn M, Sa-Nguanraksa D, O-Charoenrat P, et al.
BMC Med
. 2024 Sep;
22(1):400.
PMID: 39294656
Background: Triple-negative breast cancer (TNBC), known for its aggressiveness and limited treatment options, presents a significant challenge. Adoptive cell transfer, involving the ex vivo generation of antigen-specific T cells from...
2.
Luangwattananun P, Sangsuwannukul T, Supimon K, Thuwajit C, Chieochansin T, Sa-Nguanraksa D, et al.
Int Immunopharmacol
. 2023 Oct;
124(Pt B):111012.
PMID: 37804657
T cell-based immunotherapy has transformed cancer treatment. Nonetheless, T cell antitumor activity can be inhibited by an immune checkpoint molecule expressed on cancer cells, program death ligand 1 (PD-L1), which...
3.
Thongchot S, Jirapongwattana N, Luangwattananun P, Chiraphapphaiboon W, Chuangchot N, Sa-Nguanraksa D, et al.
Mol Cancer Ther
. 2022 Mar;
21(5):727-739.
PMID: 35313339
Dendritic cell (DC)-based T-cell activation is an alternative immunotherapy in breast cancer. The anti-programmed death ligand 1 (PD-L1) can enhance T-cell function. Nucleolin (NCL) is overexpressed in triple-negative breast cancer...
4.
Sa-Nguanraksa D, Thasripoo C, Samarnthai N, Kummalue T, Thumrongtaradol T, O-Charoenrat P
Transl Cancer Res
. 2022 Feb;
9(10):6344-6353.
PMID: 35117242
Background: Prolactin (PRL) is a polypeptide hormone secreted by the anterior pituitary to stimulate growth and differentiation of the normal mammary gland. Together with its receptor, prolactin receptor (PRLR) have...
5.
Thongchot S, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Poungvarin N, et al.
Oncol Rep
. 2021 Oct;
46(6).
PMID: 34651665
Breast cancer cell lines are widely used as an system with which to study the mechanisms underlying biological and chemotherapeutic resistance. In the present study, two novel breast cancer cell...
6.
Sa-Nguanraksa D, Mitpakdi K, Samarnthai N, Thumrongtaradol T, O-Charoenrat P
Gland Surg
. 2021 Feb;
10(1):130-142.
PMID: 33633970
Background: Breast cancer is the most frequent female malignancy in Thailand. Prolactin (PRL) and prolactin receptor (PRLR) play an important role in normal breast development and carcinogenesis of breast cancer....
7.
Pitak-Arnnop P, Meningaud J, Sirintawat N, Subbalekha K, Auychai P, Iamaroon A, et al.
J Stomatol Oral Maxillofac Surg
. 2021 Feb;
123(1):64-73.
PMID: 33524604
Purposes: To execute a review answering the following question: "Among novel coronavirus disease (COVID19) patients, what are craniomaxillofacial (CMF) manifestations?" based on the RAMESES and the German Association of Scientific...
8.
Oo K, Kamolhan T, Soni A, Thongchot S, Mitrpant C, O-Charoenrat P, et al.
BMC Cancer
. 2021 Jan;
21(1):65.
PMID: 33446140
Background: Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment...
9.
Polchai N, Sa-Nguanraksa D, Numprasit W, Thumrongtaradol T, O-Charoenrat E, O-Charoenrat P
Cancer Manag Res
. 2020 Aug;
12:5549-5559.
PMID: 32753968
Background And Purpose: Web-based prognostic calculators have been developed to inform about the use of adjuvant systemic treatments in breast cancer. CancerMath and PREDICT are two examples of web-based prognostic...
10.
Sa-Nguanraksa D, Pongthong W, Samarnthai N, Mitpakdi K, Chuangsuwanich T, Limjindaporn T, et al.
Mol Clin Oncol
. 2020 May;
12(6):511-518.
PMID: 32382417
Androgen receptor (AR) was associated with favourable outcome in luminal breast cancer. However, the role of AR in non-luminal breast cancer remains inconclusive. The aim of the present study was...